In restoring fatty acid oxidation, application of PGC1α agonist ZLN-005 or AMPK activator could significantly enhance FAO and inhibit the transition from AKI to CKD, thereby preventing the transition from AKI to CKD (Xu et al., 2023). This evidence concerns the gene PPARGC1A and chronic kidney disease.